Deakin University

当前是南半球冬季，也是澳大利亚的流感高峰期。而在既往，此时正应当是南半球的流感疫苗接种旺季——季节和越来越多的流感患者会提醒人们去接种流感疫苗，但现实是澳大利亚选择接种流感疫苗的人在变少。 南半球消失的流感疫苗接种“旺季” 据澳联邦政府7月前两周的数据显示，今年的呼吸道疾病比去年更多。 但与2023年这个时候相比，今年接种流感疫苗的澳大利亚人减少了约54万人，年度统计数字是自2020年有疫苗接种数据以来的最低水平。 对于5-64岁的人群来说，这一下降最为显著——与去年相比，今年这一年龄段的人数超过44万人选择不接种疫苗，5岁以下和65岁以上的疫苗接种率也较低。 美国国家免疫研究与监测中心（NCIRS）副主任Frank Beard表示，今年的流感疫苗接种率比去年低约2%或3%，比2022年低10%。 主要障碍：疫苗疲劳+大流行后要为生计忙碌 NCIRS的一项全国性调查的中期调查结果确定了人们不接种流感疫苗的主要原因——不接种者认为流感不严重，疫苗会让他们患上流感，或者它不会起作用。 Frank Bead教授接下来的谈话或猜想，可能也将成为2024-2025年流感季中国流感疫苗接种率困境的关键。 “自 COVID 大流行以来，似乎存在疫苗疲劳，所有注意力都集中在 COVID 疫苗接种上。 “此外，人们忙于生计，因此他们没有像应有的那样优先考虑流感疫苗接种。” 调查还显示，人们认为很难获得疫苗，而费用是一个障碍。事实上欧美国家流感疫苗没有想象的那么贵，平均20＄/剂的价格并不比我国高出太多。 他表示，接种流感疫苗比以往任何时候都容易——“所有州和地区的药剂师现在都可以接种流感疫苗，他们中的大多数药剂师可以为五岁及以上的任何人接种，高风险人群可以免费获得。” 近期中国的流感疫苗价格降到了88元/支（四价），这给了人们接种流感疫苗的契机。但问题是，中国无法像澳洲等欧美国家那样，可以便利地在药房接种到流感疫苗。2024-2025年流感季，将是流感的大流行季 在皇家墨尔本医院（RMH），急诊科在过去两周内记录了120例流感病例。 “即使在每年的这个时候，这也是一个很大的数字，”RMH呼吸科医生Lou Irving说。“显然，社区里有很多流感。” 这些数字最终将表明，这是一个大的（流感）季节。对比中国，今年可能也将是个流感大流行的年份。 根据中国疾控中心法定报告传染病数据显示，2023年5、6月份是流感的低流行期，5月报告22万余例，6月快速降至6万余例。但2024年5、6月份却有些反常，5月报告44万余例，6月仍高达31万余例——似乎这一切都意味着，我们再也回不到流感全年报告不到500万例的时代了…… 欧文教授本人不在急诊科工作，但是会负责为患有呼吸道疾病的住院患者看病，其中近期确诊的流感阳性住院患者确实在增多。 欧文教授说，虽然全国的疫苗接种率正在下降，但接种流感疫苗以防止患严重疾病的机会仍然是值得的。在他的工作中他目睹了社区获得性肺炎的增加，其中诱发因素是季节性流感。 “有些人认为流感只是短暂的两到三天的疼痛和发烧，但不幸的是，这种感染会降低对其他疾病的免疫防御能力。虽然疫苗不是100%有效，但它确实减轻了严重程度。” 疫苗疲劳可能让人错过接种疫苗最佳时机 迪肯大学流行病学主席凯瑟琳·贝内特（Catherine Bennett）表示，当前流感高峰有两个问题：每年接种流感疫苗的人数较少，以及由于大流行封锁。大量人长时间没有感染流感，因此他们的总体免疫力很低。 贝内特教授说：“令人担忧的是，随着疫苗接种率的降低，我们现在看到了影响，因为流感季节现在正处于高峰期。” “对一些人来说，存在疫苗疲劳，但当它成为一个问题时也不太清楚，因为我们一整年都在听说流感、呼吸道合胞病毒和新冠病毒。” 她说，流感疫苗并不完美，但值得接种，因为它可以降低感染风险。“如果你在流感疫苗上市的时候接种，从每年4月开始，那就是与我们的流感季节相吻合，那是疫苗最有效的时候。” 在中国，8月份开始接种是个很好的时机。这样可以在9月份达到最佳免疫水平以应对10月、11月的流感高峰——2023年9月，我国报告16万余例流感，10月份达到34万余例，而到了11月，这一数字激增至超186万例！！！ 识别微信二维码，添加生物制品圈小编，符合条件者即可加入 生物制品微信群！ 请注明：姓名+研究方向！ 版 权 声 明 本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

Working together to understand the factors which could be used to predict outcome following TBI, researchers examined factors related to social support, health, clinical care, biological markers, acute interventions, and longer-term outcomes. A team of Australia's leading health researchers has developed a new 'dictionary' to better predict outcomes for people who have experienced a moderate-severe traumatic brain injury (TBI). The Australian Traumatic Brain Injury Initiative (AUS-TBI) is a consortium of academics, researchers and healthcare professionals from institutions across the country. Working together to understand the factors which could be used to predict outcome following TBI in a study supported by the Australian Medical Research Future Fund Mission for TBI, the team examined factors related to social support, health, clinical care, biological markers, acute interventions, and longer-term outcomes. Published across eight articles in a special edition of the Journal of Neurotrauma, this work culminated in a Single Data Dictionary: a master list of information that if collected would give the best chance at understanding how a person will recover from their brain injury. Consortium lead and Curtin University Deputy Vice-Chancellor, Research Professor Melinda Fitzgerald said predicting each individual's outcome following a TBI was critical -- but also very difficult. "The rate and degree of recovery after moderate-severe TBI varies greatly, due in part to the complex and diverse nature of these injuries," Professor Fitzgerald said. "Despite decades of empirical research, prediction of outcomes after TBI for individual patients remains imprecise: we have only partial understanding of what it is about the person, their injury, their environment, or their care that moderates and/or determines the multiple outcomes that contribute to their quality of life. "At present, there is no indicator or group of indicators that can sufficiently predict treatment outcome or responsiveness to allow for personalised acute care and rehabilitation for patients with TBI." To create the Single Data Dictionary, the AUS-TBI team examined thousands of published research articles reporting factors which may impact a person's recovery, such as their medical history, social contexts, biological markers, level of personal support, effectiveness of treatment and more. The team also consulted extensively with people who have lived experience of TBIs, including an Aboriginal and Torres Strait Islander Advisory Group, to develop the Single Data Dictionary of predictive markers alongside guidelines on how to collect them in a coordinated, culturally sensitive national approach. Co-author Dr Sarah Hellewell, from Curtin's Faculty of Health Sciences, Curtin Health Innovation Research Institute and the Perron Institute, said providing personalised care to ensure the best outcomes for patients was critical, as TBIs are often catastrophic and have lifelong impact on patients, their families, workplaces, the criminal justice system and society as a whole. "Severe TBI has a mortality rate of 30-40 per cent, less than 50 per cent of patients achieve long-term independence and new injuries add $2 billion in lifetime direct costs to the Australian healthcare system each year," Dr Hellewell said. "Between 2006 and 2015, there was no change in survival or functional outcomes following TBI, proving the need for better, targeted management strategies to reduce mortality and improve quality of life for these individuals and reduce negative impacts on families and society." Organisations also involved in the consortium include the Perron Institute, Telethon Kids Institute, Monash University, Griffith University, Deakin University, University of Sydney, University of Queensland, University of Adelaide, University of Melbourne, University of Newcastle, Synapse, Hunter Medical Research Institute, John Hunter Hospital, Brightwater Care Group, The Children's Hospital at Westmead and Epworth HealthCare.

The unique program provides early-career scientists with leadership training and connections to peers from around the world COLUMBUS, Ohio, March 25, 2024 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific knowledge management, is proud to announce the 2024 CAS Future Leaders. These exceptional early-career scientists were selected from a large pool of global candidates who applied for a spot in the program known as one of the best leadership learning experiences in the world of science. Continue Reading CAS Future Leaders, 2024 The 2024 selectees are a diverse group, hailing from 13 countries, working at 33 graduate or post-doctoral programs, and specializing in scientific disciplines that span computer-aided drug design, atmospheric/environmental chemistry, sustainable polymers, and cancer diagnostics. "CAS Future Leaders offers early-career scientists the opportunity to participate in leadership and storytelling seminars, learn from industry thought leaders how to present their ideas in an impactful manner, engage in scientific discourse, and develop connections with peer scientists from around the world," said Peter Carlton, CAS Future Leaders program director. Participants in the program, which will take place in August, will also get a behind-the-scenes look into how CAS connects the world's science. They will present their research at ACS Fall 2024 in Denver, Colorado, and receive a three-year ACS membership as well. The 2024 CAS Future Leaders: Aziz Abu-Saleh, University of Windsor, Canada Noah Bartfield, Yale University, United States Michelle Brann, Harvard & Smithsonian Center for Astrophysics, United States Rosemary L. Calabro, U.S. Army DEVCOM Armaments Center and United States Military Academy, United States Xiangkun (Elvis) Cao, Massachusetts Institute of Technology, United States Áine Coogan, Trinity College Dublin, Ireland Chiara Deriu, Politecnico di Torino, Italy Madison Elaine Edwards, Texas A&M University, United States Olga Eremina, University of Southern California, United States Inès Forrest, Scripps Research Institute, United States Patrick W. Fritz, University of Fribourg, Switzerland Nabojit Kar, Indiana University Bloomington, United States Stavros Kariofillis, Columbia University, United States Joshua Kofsky, Queen's University, Canada Eric Kohn, University of Wisconsin-Madison, United States Danielle Maxwell, University of Michigan, United States Keita Mori, Tokyo University of Agriculture and Technology, Japan Aditya Nandy, University of Chicago, United States Akachukwu Obi, Massachusetts Institute of Technology, United States Ernest Opoku, Auburn University, United States Daisy Pooler, KTH Royal Institute of Technology, Sweden Pragti, Indian Institute of Technology Indore, India Stephanie Schneider, McMaster University, Canada Ekaterina Selivanovitch, Cornell University, United States Hanchen Shen, Hong Kong University of Science and Technology, China Lilian Sophie Szych, Freie Universität Berlin, Germany Alexander Umanzor, University of Minnesota, Twin Cities, United States Ken Aldren Usman, Institute for Frontier Materials, Deakin University - Waurn Ponds, Australia Sara T. R. Velasquez, University of Twente, Netherlands Gayatri Viswanathan, Iowa State University, United States Kunyu Wang, University of Pennsylvania, United States Athi Welsh, University of Cape Town, South Africa Kyra Yap, Stanford University, United States Yirui Zhang, Stanford University, United States Junyi Zhao, Washington University in St. Louis, United States In addition to the 35 in-person participants, CAS provides virtual programming and other career benefits to 65 additional outstanding selectees through the CAS Future Leaders Top 100 program. "I am thrilled to be selected for the 2024 CAS Future Leaders program alongside such an esteemed group of interdisciplinary scientists. I look forward to gaining new leadership skills and building lasting connections with peers who are as passionate as I am about science and leadership," said Michelle Brann from the Harvard & Smithsonian Center for Astrophysics. Learn more about the 2024 CAS Future Leaders program at . About CAS CAS connects the world's scientific knowledge to accelerate breakthroughs that improve lives. We empower global innovators to efficiently navigate today's complex data landscape and make confident decisions in each phase of the innovation journey. As a specialist in scientific knowledge management, our team builds the largest authoritative collection of human-curated scientific data in the world and provides essential information solutions, services, and expertise. Scientists, patent professionals, and business leaders across industries rely on CAS to help them uncover opportunities, mitigate risks, and unlock shared knowledge so they can get from inspiration to innovation faster. CAS is a division of the American Chemical Society. Connect with us at cas.org. Photo - Logo -